Management of Dyslipidaemia in Real-world Clinical Practice: Rationale and Design of the VIPFARMA ISCP Project

Dyslipidaemia plays a major role in the pathogenesis of atherosclerosis. Every year, scientific institutions publish cardiovascular prevention guidelines with updated goals and recommendations based on new evidence. However, medical barriers exist that make achieving these goals difficult and gaps b...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ricardo Lopez Santi, Felipe Martinez, Adrian Baranchuk, Alvaro Sosa Liprandi, Daniel Piskorz, Alberto Lorenzatti, Juan Carlos Kaski
Formato:	article
Lenguaje:	EN
Publicado:	Radcliffe Medical Media 2021
Materias:	Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/4cc6b34f5eb04d13b4ba90713e405361
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4cc6b34f5eb04d13b4ba90713e405361
record_format	dspace
spelling	oai:doaj.org-article:4cc6b34f5eb04d13b4ba90713e4053612021-12-04T16:04:22ZManagement of Dyslipidaemia in Real-world Clinical Practice: Rationale and Design of the VIPFARMA ISCP Project10.15420/ecr.2020.421758-37641758-3756https://doaj.org/article/4cc6b34f5eb04d13b4ba90713e4053612021-04-01T00:00:00Zhttps://www.ecrjournal.com/articleindex/ecr.2020.42https://doaj.org/toc/1758-3756https://doaj.org/toc/1758-3764Dyslipidaemia plays a major role in the pathogenesis of atherosclerosis. Every year, scientific institutions publish cardiovascular prevention guidelines with updated goals and recommendations based on new evidence. However, medical barriers exist that make achieving these goals difficult and gaps between guidelines and best daily clinical practice still persist. The International Society of Cardiovascular Pharmacotherapy designed the Surveillance of Prescription Drugs in the Real World Project (VIPFARMA ISCP), a survey for physicians who manage lipid disorders in high-risk patients. Seven clusters of questions will be analysed comprising demographics, institution profile, access to continuing medical education, clinical practice profile, attitude regarding use of statins, knowledge regarding proprotein convertase subtilisin/kexin type 9 inhibitors and attitudes regarding medical decisions about triglycerides. The present study will be the first part of a larger programme and aims to shed light on barriers between lipid-lowering drug therapy recommendations in the 2019 European Society of Cardiology guidelines and clinical practice in different countries.Ricardo Lopez SantiFelipe MartinezAdrian BaranchukAlvaro Sosa LiprandiDaniel PiskorzAlberto LorenzattiJuan Carlos KaskiRadcliffe Medical MediaarticleDiseases of the circulatory (Cardiovascular) systemRC666-701ENEuropean Cardiology Review , Vol 16, Iss , Pp - (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	Diseases of the circulatory (Cardiovascular) system RC666-701 Ricardo Lopez Santi Felipe Martinez Adrian Baranchuk Alvaro Sosa Liprandi Daniel Piskorz Alberto Lorenzatti Juan Carlos Kaski Management of Dyslipidaemia in Real-world Clinical Practice: Rationale and Design of the VIPFARMA ISCP Project
description	Dyslipidaemia plays a major role in the pathogenesis of atherosclerosis. Every year, scientific institutions publish cardiovascular prevention guidelines with updated goals and recommendations based on new evidence. However, medical barriers exist that make achieving these goals difficult and gaps between guidelines and best daily clinical practice still persist. The International Society of Cardiovascular Pharmacotherapy designed the Surveillance of Prescription Drugs in the Real World Project (VIPFARMA ISCP), a survey for physicians who manage lipid disorders in high-risk patients. Seven clusters of questions will be analysed comprising demographics, institution profile, access to continuing medical education, clinical practice profile, attitude regarding use of statins, knowledge regarding proprotein convertase subtilisin/kexin type 9 inhibitors and attitudes regarding medical decisions about triglycerides. The present study will be the first part of a larger programme and aims to shed light on barriers between lipid-lowering drug therapy recommendations in the 2019 European Society of Cardiology guidelines and clinical practice in different countries.
format	article
author	Ricardo Lopez Santi Felipe Martinez Adrian Baranchuk Alvaro Sosa Liprandi Daniel Piskorz Alberto Lorenzatti Juan Carlos Kaski
author_facet	Ricardo Lopez Santi Felipe Martinez Adrian Baranchuk Alvaro Sosa Liprandi Daniel Piskorz Alberto Lorenzatti Juan Carlos Kaski
author_sort	Ricardo Lopez Santi
title	Management of Dyslipidaemia in Real-world Clinical Practice: Rationale and Design of the VIPFARMA ISCP Project
title_short	Management of Dyslipidaemia in Real-world Clinical Practice: Rationale and Design of the VIPFARMA ISCP Project
title_full	Management of Dyslipidaemia in Real-world Clinical Practice: Rationale and Design of the VIPFARMA ISCP Project
title_fullStr	Management of Dyslipidaemia in Real-world Clinical Practice: Rationale and Design of the VIPFARMA ISCP Project
title_full_unstemmed	Management of Dyslipidaemia in Real-world Clinical Practice: Rationale and Design of the VIPFARMA ISCP Project
title_sort	management of dyslipidaemia in real-world clinical practice: rationale and design of the vipfarma iscp project
publisher	Radcliffe Medical Media
publishDate	2021
url	https://doaj.org/article/4cc6b34f5eb04d13b4ba90713e405361
work_keys_str_mv	AT ricardolopezsanti managementofdyslipidaemiainrealworldclinicalpracticerationaleanddesignofthevipfarmaiscpproject AT felipemartinez managementofdyslipidaemiainrealworldclinicalpracticerationaleanddesignofthevipfarmaiscpproject AT adrianbaranchuk managementofdyslipidaemiainrealworldclinicalpracticerationaleanddesignofthevipfarmaiscpproject AT alvarososaliprandi managementofdyslipidaemiainrealworldclinicalpracticerationaleanddesignofthevipfarmaiscpproject AT danielpiskorz managementofdyslipidaemiainrealworldclinicalpracticerationaleanddesignofthevipfarmaiscpproject AT albertolorenzatti managementofdyslipidaemiainrealworldclinicalpracticerationaleanddesignofthevipfarmaiscpproject AT juancarloskaski managementofdyslipidaemiainrealworldclinicalpracticerationaleanddesignofthevipfarmaiscpproject
_version_	1718372670965284864

Management of Dyslipidaemia in Real-world Clinical Practice: Rationale and Design of the VIPFARMA ISCP Project

Ejemplares similares